Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

First International Summit on Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Jan

Today In Oncology

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Related Videos

Deborah Collyar: What's In It for Patients?

Opportunities to Optimize Cancer Policies Panel Discussion

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer

Nivolumab Plus AVD Reduces Disease Progression Risk in Advanced Classical Hodgkin Lymphoma

WGS-Based Classifier Better Predicts HRD Across Cancer Types

ACS Report Shows 5-Year Survival Rate for All Cancers Combined Has Reached 70%